INmune Bio, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $50.8M
- Price
- $1.83
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.61%
- Volume
- 379.2K
About
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
Quick stats
Shares outstanding27.8M
Computed float24.8M
Float / shares89.2%
Cash runway (months)19
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001711754
Websitehttps://www.inmunebio.com
AI Summary
AI-generated1/27
minorneutralother
INmune Bio to Attend the 2026 Maxim Growth Summit
INmune Bio announced its participation in the 2026 Maxim Growth Summit, held October 12-14 at The Hard Rock Hotel NYC.
CEO David Moss will present on an Immunology & Inflammation Therapies Panel on October 14 at 10:30am, and the company will hold one-on-one meetings with institutional investors.
The release reiterates late-stage pipeline milestones, including a planned CORDStrom MAA filing in the UK in 2026 and an XPro1595 Phase 2b/3 registrational program in early Alzheimer's disease, but contains no new data or financial figures.